Why should I give both mycophenolate mofetil (MMF) and nintedanib in systemic sclerosis-associated interstitial lung disease?

Combination Therapy with MMF and Nintedanib in SSc-ILD

You should consider combining MMF and nintedanib in SSc-ILD when patients present with advanced disease at initial presentation, demonstrate aggressive ILD progression, or show significant disease progression despite immunosuppressive monotherapy. 1, 2

Rationale for Combination Therapy

Complementary Mechanisms of Action

• MMF provides immunosuppression by inhibiting lymphocyte proliferation and addressing the inflammatory component of SSc-ILD 1
• Nintedanib offers antifibrotic effects through tyrosine kinase inhibition, targeting the fibrotic progression independent of immune mechanisms 2, 3
• The synergistic approach addresses both pathophysiologic pathways simultaneously—inflammation and fibrosis—which are both active in SSc-ILD 4, 5

Evidence Supporting Combination Use

The SENSCIS trial demonstrated that nintedanib's efficacy was preserved in patients already taking MMF, with no heterogeneity in treatment effect between those on or off MMF at baseline (p=0.45 for interaction). 6 Specifically:

• In patients taking MMF at baseline, nintedanib reduced FVC decline by 26.3 mL/year compared to placebo 6
• In patients not taking MMF, the reduction was 55.4 mL/year 6
• The adverse event profile was similar regardless of MMF use, with diarrhea occurring in 76% on combination versus 75% on nintedanib alone 6

Current Guideline Recommendations

For first-line treatment, guidelines conditionally recommend AGAINST upfront combination therapy in stable SSc-ILD without progression. 1 However, this changes with disease progression:

• For progressive SSc-ILD despite first-line therapy, guidelines conditionally recommend ADDING nintedanib 1
• The EULAR 2023 guidelines explicitly state nintedanib should be considered alone OR in combination with MMF for SSc-ILD treatment 2
• Expert consensus supports concomitant use in patients with advanced disease at presentation, aggressive ILD, or significant progression 7

Clinical Scenarios Favoring Combination Therapy

Progressive Fibrosing ILD

• Patients meeting INBUILD criteria for progressive fibrosing ILD (FVC decline ≥10% predicted, or FVC decline 5-10% with worsening symptoms/increased fibrosis on HRCT within 24 months) should receive nintedanib added to immunosuppression 1, 2
• The INBUILD trial showed nintedanib reduced FVC decline by 102.7 mL/year in progressive fibrosing autoimmune ILDs including SSc-ILD 2

Extensive Disease at Presentation

• Patients with extensive fibrosis on HRCT at initial diagnosis warrant consideration of upfront combination therapy 7
• Those with rapidly declining lung function (FVC decline >10% within 6-12 months) benefit from dual mechanism targeting 7

Inadequate Response to Monotherapy

• When MMF alone fails to stabilize disease after 6 months, adding nintedanib is recommended over switching agents 1
• This sequential approach is preferred over upfront combination in most cases to minimize polypharmacy and side effects 1

Important Safety Considerations

Gastrointestinal Adverse Effects

• Diarrhea is the most common adverse event, occurring in 76% of patients on combination therapy versus 34% on placebo with MMF 6
• Nausea and vomiting led to treatment interruptions in 20.6% of patients in real-world cohorts 8
• Proactive management with antidiarrheals and antiemetics is essential to maintain treatment adherence 8

Weight Loss and Nutritional Monitoring

• Patients with BMI <18.5 kg/m² are at significantly higher risk for treatment interruption (p=0.024) 8
• Mean weight loss after nintedanib initiation (2.05 kg) was significantly greater than before treatment (1.09 kg, p=0.001) 8
• Close nutritional monitoring and support are mandatory, particularly in underweight patients 8

Monitoring Requirements

• Complete blood counts weekly for the first month, then twice monthly for months 2-3, then monthly through year 1 for MMF toxicity 9
• Liver function tests should be monitored regularly as both agents can cause hepatotoxicity 9
• Pregnancy testing is mandatory for females of reproductive potential due to MMF's teratogenicity 9

Practical Implementation Algorithm

Start with MMF monotherapy (1-1.5g twice daily) as first-line treatment in most SSc-ILD patients 1

Add nintedanib (150mg twice daily, or 100mg twice daily if not tolerated) if:

• FVC declines ≥10% predicted over 6-12 months 1, 2
• FVC declines 5-10% with worsening dyspnea or increased fibrosis on HRCT 1, 2
• Extensive fibrosis present at initial diagnosis with aggressive clinical course 7

Consider upfront combination only in:

• Very extensive ILD (>20% lung involvement on HRCT) at presentation 7
• Rapidly progressive disease with FVC decline >10% in <6 months 7
• High-risk features including anti-topoisomerase I antibodies with diffuse cutaneous SSc 6

Avoid combination therapy in:

• Stable disease without progression on MMF alone 1
• Patients with BMI <18.5 kg/m² without aggressive nutritional support 8
• Active peptic ulcer disease or severe gastrointestinal disorders 9